

Anus

Protocol applies to all invasive carcinomas of the anal canal.

*Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Excisional Biopsy (Polypectomy)**
- **Local Excision (Transanal Disk Incision)**
- **Abdominoperineal Resection**

Authors

Carolyn C. Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada

R. R. Rickert, MD

Department of Pathology, St. Barnabas Medical Center, Livingston, New Jersey

For the Members of the Cancer Committee, College of American Pathologists

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

ANUS: Excisional Biopsy (Polypectomy)

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC***Tumor Site**

* Specify, if known: _____

* ___ Not specified

Polyp Size

Greatest dimension: ___ cm

*Additional dimensions: ___x___ cm

___ Cannot be determined (see Comment)

***Polyp Configuration**

* ___ Pedunculated, with stalk

*Stalk length: ___ mm

* ___ Pedunculated, no stalk, narrow-based

* ___ Sessile/broad-based

* ___ Cannot be determined

MICROSCOPIC**Histologic Type**

___ Squamous cell carcinoma

___ Adenocarcinoma

___ Mucinous adenocarcinoma

___ Small cell carcinoma

___ Undifferentiated carcinoma

___ Other (specify): _____

___ Carcinoma, type cannot be determined

4

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Histologic Grade (if applicable to tumor type)

- Not applicable
 GX: Cannot be assessed
 G1: Well differentiated
 G2: Moderately differentiated
 G3: Poorly differentiated
 G4: Undifferentiated

Extent of Invasion

- Epithelium only (no invasion)
 Invasion (deepest):
 Cannot be determined
 Into lamina propria
 Into muscularis mucosae
 Into submucosa

Polyp Resection Margin (check all that apply)

- Cannot be assessed
 Uninvolved by invasive carcinoma
 Distance of invasive carcinoma from margin: ____ mm
 Carcinoma in situ absent at mucosal margin
 Carcinoma in situ present at mucosal margin
 Involved by invasive carcinoma
 Not applicable (specify reason): _____

Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)

- Not applicable
 Absent
 Present
 Indeterminate

***Additional Pathologic Findings (check all that apply)**

- * None identified
 * Active colitis
 * Other (specify): _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

ANUS: Local Excision (Transanal Disk Excision)

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Integrity** Intact Fragmented

*Number of pieces in fragmented specimens: ____

 Other (specify): _____***Tumor Site*** Unknown

* Specify, if known: _____

Tumor Size

Greatest dimension: ____ cm

*Additional dimensions: ____ x ____ cm

 Cannot be determined (see Comment)***Tumor Configuration*** Polypoid* Infiltrative* Ulcerating* Other (specify): _____

6 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

MICROSCOPIC**Histologic Type**

- Squamous cell carcinoma
 Adenocarcinoma
 Mucinous adenocarcinoma
 Small cell carcinoma
 Undifferentiated carcinoma
 Paget disease
 Other (specify): _____
 Carcinoma, type cannot be determined

Histologic Grade

- Not applicable
 GX: Cannot be assessed
 G1: Well differentiated
 G2: Moderately differentiated
 G3: Poorly differentiated
 G4: Undifferentiated
 Other (specify): _____

Pathologic Staging (pTNM)Primary Tumor (pT)

- pTX: Cannot be assessed
 pT0: No evidence of primary tumor
 pTis: Carcinoma in situ
 pT1: Tumor 2 cm or less in greatest dimension
 pT2: Tumor more than 2 cm but not more than 5 cm in greatest dimension
 pT3: Tumor more than 5 cm in greatest dimension
 pT4: Tumor of any size with invasion of adjacent organ(s); eg, vagina, urethra, bladder (involvement of sphincter muscles alone is not classified as T4).

Margins (check all that apply)

- Cannot be assessed
 Margins uninvolved by invasive carcinoma
 Distance of invasive carcinoma from closest margin: ____ mm
 Specify margin (if possible): _____
 Carcinoma in situ absent at lateral mucosal margin
 Carcinoma in situ present at lateral mucosal margin
 Margin(s) involved by invasive carcinoma
 Not applicable (specify reason): _____

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

***Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- * Absent
- * Present
- * Indeterminate

***Perineural Invasion**

- * Absent
- * Present

***Additional Pathologic Findings (check all that apply)**

- * None identified
- * Crohn disease
- * Condyloma accuminatum
- * Dysplasia
- * Associated rectal carcinoma (Paget disease)
- * Other (specify): _____

***Comment(s)**

8 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

ANUS: Resection

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type** Abdominoperineal resection Other (specify): _____ Not specified**Tumor Site (check all that apply)** Anterior wall Anal margin Not specified**Tumor Size**

Greatest dimension: ___ cm

*Additional dimensions: ___x___ cm

 Cannot be determined (see Comment)***Tumor Configuration:*** Polypoid* Infiltrative* Ulcerating* Other (specify): _____

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

MICROSCOPIC**Histologic Type**

- Squamous cell carcinoma
 Adenocarcinoma
 Mucinous adenocarcinoma
 Small cell carcinoma
 Undifferentiated carcinoma
 Paget disease
 Other (specify): _____
 Carcinoma, type cannot be determined

Histologic Grade

- Not applicable
 GX: Cannot be assessed
 G1: Well differentiated
 G2: Moderately differentiated
 G3: Poorly differentiated
 G4: Undifferentiated

Pathologic Staging (pTNM)Primary Tumor (pT)

- pTX: Cannot be assessed
 pT0: No evidence of primary tumor
 pTis: Carcinoma in situ
 pT1: Tumor 2 cm or less in greatest dimension
 pT2: Tumor more than 2 cm but not more than 5 cm in greatest dimension
 pT3: Tumor more than 5 cm in greatest dimension
 pT4: Tumor of any size with invasion of adjacent organ(s); eg, vagina, urethra, bladder (involvement of sphincter muscles alone is not classified as T4).

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
 pN0: No regional lymph node metastasis
 pN1: Metastasis in perirectal lymph nodes
 pN2: Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
 pN3: Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes

Specify: Number examined: ____
 Number involved: ____

Distant Metastasis (pM)

- pMX: Cannot be assessed
 pM1: Distant metastasis
 *Specify site(s), if known: _____

Margins (check all that apply)Proximal Margin

- Cannot be assessed
 Uninvolved by invasive carcinoma
 Carcinoma in situ absent at mucosal margin
 Carcinoma in situ present at mucosal margin
 Involved by invasive carcinoma

Distal Margin

- Cannot be assessed
 Uninvolved by invasive carcinoma
 Carcinoma in situ absent at mucosal margin
 Carcinoma in situ present at mucosal margin
 Involved by invasive carcinoma

Circumferential (Radial) Margin

- Cannot be assessed
 Uninvolved by invasive carcinoma
 Involved by invasive carcinoma

If all margins uninvolved by invasive carcinoma:

Distance of invasive carcinoma from closest margin: ___ mm

Specify margin: _____

***Perineural Invasion**

- * Absent
 * Present

***Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- * Absent
 * Present
 * Indeterminate

***Additional Pathologic Findings (check all that apply)**

- * None identified
 * Crohn disease
 * Condyloma acuminatum
 * Dysplasia
 * Associated rectal carcinoma (Paget disease)
 * Other (specify): _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.